Patents by Inventor Patrick Altermatt

Patrick Altermatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-SUBSTITUTED FERROPORTIN INHIBITORS
    Publication number: 20240343722
    Abstract: The invention relates to novel compounds of the general formula (1-A) as defined in the application and pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
    Type: Application
    Filed: September 20, 2022
    Publication date: October 17, 2024
    Applicant: VIFOR (INTERNATIONAL) AG
    Inventors: Wilm BUHR, Aris KALOGERAKIS, Klaus-Daniel UMLAND, Stefan REIM, Vania MANOLOVA, Patrick ALTERMATT, Anna FLACE
  • MODIFIED FERROPORTIN INHIBITORS
    Publication number: 20240239780
    Abstract: The invention relates to novel compounds of the general formula (I), which are characterized in that at least one of the groups A and B contains at least 3 rings, pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the use as ferroportin inhibitors, more particularly for the use in the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders leading to increased iron levels or increased iron absorption, and/or iron overload.
    Type: Application
    Filed: April 21, 2022
    Publication date: July 18, 2024
    Applicant: Vifor (International) AG
    Inventors: Wilm BUHR, Aris KALOGERAKIS, Klaus-Daniel UMLAND, Stefan REIM, Vania MANOLOVA, Patrick ALTERMATT, Anna FLACE
  • Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT)
    Publication number: 20220273634
    Abstract: The invention relates to the use of ferroportin inhibitor compounds of the general formula (I) for treating transfusion-dependent ?-thalassemia.
    Type: Application
    Filed: July 17, 2020
    Publication date: September 1, 2022
    Inventors: Vania Manolova, Naja Nyffenegger, Patrick Altermatt, Franz Dürrenberger